June 17, 2025

Aconitine Tames Joints, Protects Bone

At EULAR 2025, researchers presented data showing aconitine reduced bone erosion and increased regulatory T cells in a rheumatoid arthritis mouse model.

Conexiant

June 16, 2025

Can Gout Therapy Protect Hearts Too?

New research shows achieving serum urate targets within1 year may significantly reduce major cardiovascular events in gout patients.

Conexiant

June 16, 2025

Updated Guidance on Antirheumatic Drug Use

New 2024 EULAR recommendations offer evidence-based guidance for the use of antirheumatic drugs during pregnancy, lactation, and conception planning in patients with rheumatic and musculoskeletal diseases.

Conexiant

June 13, 2025

JAK Inhibitors Show No Increased Cancer Risk

New real-world data show no significant rise in overall cancer incidence with JAK inhibitors for rheumatoid arthritis patients, though skin cancer monitoring remains important.

Conexiant

June 12, 2025

Gene Variants Linked to CPPD Risk

A large genetic study in U.S. veterans has identified ENPP1 and RNF144B as genes associated with calcium pyrophosphate deposition disease, suggesting potential for targeted treatment approaches.

Conexiant

June 09, 2025

NIH Staff Challenge Leadership's Research Policies

Federal scientists release formal dissent declaration opposing administration's grant terminations and policy changes affecting biomedical research.

Conexiant

June 06, 2025

Shifting Views Linked to Fewer Joint Surgeries, Study 

A Swedish study found that patients with knee or hip osteoarthritis who became unwilling to have joint replacement after a 3-month education and exercise program were significantly less likely to undergo surgery over the next several years.

Conexiant

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

May 27, 2025

New FDA approved Biosimilar Targets IL-12/23

The FDA has approved Starjemza, a ustekinumab biosimilar, for multiple inflammatory conditions.

Conexiant